TY - JOUR
T1 - The global burden of metabolic disease
T2 - Data from 2000 to 2019
AU - Chew, Nicholas W.S.
AU - Ng, Cheng Han
AU - Tan, Darren Jun Hao
AU - Kong, Gwyneth
AU - Lin, Chaoxing
AU - Chin, Yip Han
AU - Lim, Wen Hui
AU - Huang, Daniel Q.
AU - Quek, Jingxuan
AU - Fu, Clarissa Elysia
AU - Xiao, Jieling
AU - Syn, Nicholas
AU - Foo, Roger
AU - Khoo, Chin Meng
AU - Wang, Jiong Wei
AU - Dimitriadis, Georgios K.
AU - Young, Dan Yock
AU - Siddiqui, Mohammad Shadab
AU - Lam, Carolyn S.P.
AU - Wang, Yibin
AU - Figtree, Gemma A.
AU - Chan, Mark Y.
AU - Cummings, David E.
AU - Noureddin, Mazen
AU - Wong, Vincent Wai Sun
AU - Ma, Ronald Ching Wan
AU - Mantzoros, Christos S.
AU - Sanyal, Arun
AU - Muthiah, Mark Dhinesh
N1 - Publisher Copyright:
© 2023 Elsevier Inc.
PY - 2023/3/7
Y1 - 2023/3/7
N2 - Global estimates of prevalence, deaths, and disability-adjusted life years (DALYs) from the Global Burden of Diseases, Injuries, and Risk Factors Study 2019 were examined for metabolic diseases (type 2 diabetes mellitus [T2DM], hypertension, and non-alcoholic fatty liver disease [NAFLD]). For metabolic risk factors (hyperlipidemia and obesity), estimates were limited to mortality and DALYs. From 2000 to 2019, prevalence rates increased for all metabolic diseases, with the greatest increase in high socio-demographic index (SDI) countries. Mortality rates decreased over time in hyperlipidemia, hypertension, and NAFLD, but not in T2DM and obesity. The highest mortality was found in the World Health Organization Eastern Mediterranean region, and low to low-middle SDI countries. The global prevalence of metabolic diseases has risen over the past two decades regardless of SDI. Urgent attention is needed to address the unchanging mortality rates attributed to metabolic disease and the entrenched sex-regional-socioeconomic disparities in mortality.
AB - Global estimates of prevalence, deaths, and disability-adjusted life years (DALYs) from the Global Burden of Diseases, Injuries, and Risk Factors Study 2019 were examined for metabolic diseases (type 2 diabetes mellitus [T2DM], hypertension, and non-alcoholic fatty liver disease [NAFLD]). For metabolic risk factors (hyperlipidemia and obesity), estimates were limited to mortality and DALYs. From 2000 to 2019, prevalence rates increased for all metabolic diseases, with the greatest increase in high socio-demographic index (SDI) countries. Mortality rates decreased over time in hyperlipidemia, hypertension, and NAFLD, but not in T2DM and obesity. The highest mortality was found in the World Health Organization Eastern Mediterranean region, and low to low-middle SDI countries. The global prevalence of metabolic diseases has risen over the past two decades regardless of SDI. Urgent attention is needed to address the unchanging mortality rates attributed to metabolic disease and the entrenched sex-regional-socioeconomic disparities in mortality.
KW - diabetes mellitus
KW - disability-adjusted life years
KW - disparity
KW - global burden
KW - global burden of disease
KW - hypertension
KW - metabolic disease
KW - mortality
KW - non-alcoholic fatty liver disease
KW - obesity
KW - Quality-Adjusted Life Years
KW - Hypertension
KW - Metabolic Diseases/epidemiology
KW - Humans
KW - Risk Factors
KW - Obesity/epidemiology
KW - Diabetes Mellitus, Type 2/epidemiology
KW - Global Burden of Disease
KW - Non-alcoholic Fatty Liver Disease
UR - http://www.scopus.com/inward/record.url?scp=85149699628&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85149699628&partnerID=8YFLogxK
U2 - 10.1016/j.cmet.2023.02.003
DO - 10.1016/j.cmet.2023.02.003
M3 - Article
C2 - 36889281
AN - SCOPUS:85149699628
SN - 1550-4131
VL - 35
SP - 414-428.e3
JO - Cell Metabolism
JF - Cell Metabolism
IS - 3
ER -